Even as BAT expands beyond trial criteria, patients see gains in LVEF, symptoms, and more. A survival impact remains unclear.

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter2025 year-end cash and cash equivalents of $226.

NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released The New Growth Frontier. This new analysis, ...

Comprehensive Enterprise Evidence-Based Patient Activation Intelligence Solution Connects Healthcare Value-Based Care Strategy to Measurable Results Across Access, Referral Closure, Care Transitions, ...

Spinal cord injury often triggers a cascade of secondary damage that severely limits functional recovery, largely driven by ...

NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released The New Growth Frontier. This new analysis, produced in collaboration with Kearney, reveals that artificial intelligence ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

At the invitation of His Excellency Narendra Modi, Prime Minister of India, the Right Honourable Mark Carney, Prime Minister of Canada, paid an official visit to India from February 27 -- March 2, ...

Researchers led by Mika Kivimaki and Staffan Nyberg at University College London have linked obesity to roughly one in 10 ...

RidePair Highlights SEP Grant Qualification Pairing Platform Positioned to Deliver Immediate Emissions Reductions and ...

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of ...

Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.